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Background: Posttranslational protein modifications are known to modulate key biological processes like proliferation
and apoptosis. Accumulating evidence shows that ST6GAL1, an enzyme that catalyzes the transfer of sialic acid onto
galactose-containing substrates, is aberrantly expressed in various cancers and may affect cell motility and invasion.
This is the first study to describe ST6GAL1 expression and regulation in human bladder cancer.
Methods: ST6GAL1 mRNA expression levels in human cell lines (UROtsa, RT4, RT112 and J82) and tissue samples
(n = 15 normal urothelium (NU), n = 13 papillary non-invasive tumors (pTa), n = 12 carcinoma in situ (CIS), n = 26
muscle invasive tumors (pT2-4)) were assessed using real-time PCR. In addition, ST6GAL1 protein expression was
evaluated using immunohistochemistry. Promoter methylation analysis was performed using methylation-specific
PCR (MSP) in cell lines (n = 4) and patient samples (n = 23 NU, n = 12 CIS, n = 29 pTa, n = 41 pT2-4). Epigenetic
ST6GAL1 gene silencing was confirmed by in vitro demethylation of bladder cell lines. Data were validated by analysis
of an independent bladder tumor data set (n = 184) based on The Cancer Genome Atlas (TCGA) portal.
Results: Semi-quantitative ST6GAL1 real-time PCR expression analysis showed two distinct trends: In muscle-invasive
tumors ST6GAL1 expression was downregulation by 2.7-fold, while papillary non-invasive tumors showed an increased
ST6GAL1 mRNA expression compared to normal urothelium. ST6GAL1 loss in muscle-invasive tumors was associated
with increasing invasiveness. On the protein level, 69.2% (n = 45/65) of all tumors showed a weak ST6GAL1 protein staining
(IRS ≤ 4) while 25.6% (16/65) exhibited a complete loss (IRS = 0) of ST6GAL1 protein. Tumor-specific DNA methylation of
the ST6GAL1 promoter region was frequently found in pT2-4 tumors (53.6% (22/41)), whereas only 13.8% (4/29) of pTa
tumors showed ST6GAL1 promoter methylation. Normal urothelium remained unmethylated. Importantly, we significantly
revealed an inverse correlation between ST6GAL1mRNA expression and ST6GAL1 promoter merthylation in primary bladder
cancer. These findings were clearly verified by the TCGA public data set and in vitro demethylation assays functionally
confirmed ST6GAL1 promoter methylation as a potential regulatory factor for ST6GAL1 gene silencing.
Conclusions: Our study characterizes for the first time ST6GAL1 expression loss caused by aberrant ST6GAL1 promoter
methylation potentially indicating a tumor suppressive role in bladder carcinogenesis.
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Urinary bladder cancer currently represents the 5th most
common cancer type in the industrialized nations [1].
Clinically, bladder cancer poses a unique clinical chal-
lenge, consisting of a heterogeneous group with either
recurrent, but relatively benign course or progressive
oncological course [2]. In 90% of cases, tumors arise
from superficial cell layers in the urogenital tract known* Correspondence: edahl@ukaachen.de
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unless otherwise stated.as urothelial cells (formerly transitional cells) [3]. Here,
two major growth forms, papillary non-invasive and flat-
invasive, have been identified, underlying two separate
molecular pathways characterized by distinct mutations
[4]. Low-grade tumors, which display a papillary growth
form and are mostly superficial (Ta low grade urothelial
carcinoma (UC)), constitute the largest group at diagnosis,
and are characterized by their high recurrence rate. The
second group is formed by high-grade tumors and in-
cludes carcinoma in situ (CIS), a flat high-grade lesion,
which in 60–80% of cases progresses to invasive bladderLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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often characterized by mutations in fibroblast growth
factor receptor 3 (FGFR3) [5,6] and rat sarcoma (RAS)
genes [5,7], while flat carcinoma in situ lesions frequently
show mutations in TP53 in addition to a loss of heterozy-
gosity of the retinoblastoma (RB) gene [3,5,8,9]. As such
high grade tumors progress to a muscle invasive stage, an
ever increasing degree of DNA hypermethylation is
observed [10]. Current research aims to further elucidate
the changes defining these divergent growth forms given
their different clinical impact and therapeutic needs.
Post-translational modifications are known to influence
protein characteristics such as protein folding and stability,
thus modulating biological processes like cell growth and
migration [11]. As a result, altered glycosylation of proteins,
such as cell surface glycoproteins and glycolipids, is a com-
mon and frequent feature during carcinogenesis, due to
impaired activity of glycosyltransferases [12]. The ST6GAL1
gene encodes a type II membrane protein (beta-galactosa-
mide alpha-2,6-sialyltransferase 1, ST6GAL1) that catalyzes
the transfer of sialic acid from cytidine-monophosphate
(CMP)-sialic acid onto galactose-containing substrates
[12-14]. Previous studies have shown that ST6GAL1 func-
tions as a critical regulator of cell survival in several cell
death pathways [14,15]. For example, its sialylation of the
Fas death receptor hinders internalization of Fas after acti-
vation, thereby reducing apoptotic signaling [14]. Similarly,
ST6GAL1 promotes cell surface retention of the tumor
necrosis factor receptor 1 (TNFR1) and the CD45 receptor
[14,15]. Furthermore in vitro studies have shown that
ST6GAL1 upregulation promotes cell migration and inva-
sion through its interaction with the B1 integrin receptor
[16-19], while animal models of colon cancer implicate
ST6GAL1 in tumor invasiveness [20]. While these studies
clearly underline the oncogenic potential of ST6GAL1,
seemingly contradictory evidence has emerged suggesting it
may also have tumor suppressive qualities [21]. For
example, recent studies clearly showed that a downregula-
tion of ST6GAL1 activity in colorectal carcinoma cell lines
facilitated cell proliferation and tumor growth [21].
However, the impact of ST6GAL1 in bladder cancer
remains unclear to date. We found ST6GAL1 downregu-
lated in bladder cancer samples in a previous metg001A
Affymetrix® GeneChip study reported by Wild et al. [22].
Therefore, the current study seeks to further elucidate
ST6GAL1 expression and its regulation in order to
determine the potential impact of the glycosyltransferase
ST6GAL1 on bladder cancer development.
Methods
Urothelial cell lines
The human SV40-transfected urothelial cell line UROtsa,
initially generated from normal ureter tissue, and the
papillary-invasive urinary bladder cancer cell lines RT4and RT112, as well as the invasive bladder cancer cell line
J82 from ATCC (American Type Culture Collection,
Manassas, Virginia, USA) were cultivated according to the
manufacturer’s instructions.
Patient materials
Formalin fixed paraffin embedded (FFPE) tumorous bladder
tissue samples analyzed in this study were obtained from
our pathology archive and the “whole bladder sampling
project (bladder mapping)” integrated in the tumor bank of
the Euregional comprehensive Cancer Center Aachen
(ECCA), now part of the RWTH centralized biomaterial
bank (RWTH cBMB; http://www.cbmb.rwth-aachen.de).
All cBMB patients gave written informed consent for re-
tention and analysis of their tissue for research purposes
according to local Institutional Review Board (IRB)-ap-
proved protocols (approval no. EK-206/09, EK-122/04 and
EK 173/06) of the medical faculty of the RWTH Aachen
University. For cohort characteristics of all analyzed sam-
ples see Table 1. Additionally, 15 normal tissue samples of
patients were used. In order to prevent contamination
from surrounding tissue, urothelium or tumor tissue was
isolated from multiple tissue sections via manual micro-
dissection under a stereo microscope, respectively.
DNA and RNA extraction
DNA extraction was achieved using the QiAmp-DNA-
Mini-Kit (Qiagen, Hilden, Germany), according to the
manufacturer’s instructions. RNA was isolated using the
TRIzol approach specified by the manufacturers (Invitrogen,
Carlsbad/CA, USA).
Reverse Transcription PCR (RT-PCR)
A total of 1 μg RNA was translated into cDNA using the
Promega-Reverse-Transcription-System (Promega, Madison/
WI, USA), according to the manufacturer’s instructions
In order to maximize the cDNA yield, Oligo-dTs and
hexameric random primers (pdN(6)) were mixed in a
ratio of 1:2. A total of 1 μl cDNA (20 ng) was used for
the PCR reaction.
Semi-quantitative real-time PCR
Real-time PCRs were performed using the iCycler system
iQ5 (Bio-Rad Laboratories, Munich) with an intron
bridging primer, according to the manufacturer’s in-
structions. The ubiquitous housekeeping gene glyerade-
hyde 3-phosphate dehydrogenase (GAPDH) was used as
a reference gene. For analysis, a cut off value for
GAPDH was assigned at a value of 30. The sequences
of the applied primers were as follows: GAPDH 5′-
sense: 5′-GAA GGT GAA GGT CGG AGT CA-3′; 3′-
antisense: 5′-AAT GAA GGG CTC ATT GAT GG-3′
with a product size of 108bp. ST6GAL1 5′-sense: 5′-
TGT CTA GAA AAG AAG GTG GAG ACA T-3′; 3′-
Table 1 Clinico-pathological parameters of all 109 bladder
cancer specimens analyzed in this study (RT-PCR/MSP/
immunohistochemistry)
Categorization na analyzable %
Parameter:
Age at diagnosis: Median: 69 years
(range 26–94)
≤69 years 55 50.5
>69 years 54 49.5
Gender
Female 29 26.6
Male 80 73.4
Tumor subtype
Carcinoma in situ 13 11.9
Papillary non-invasive 17 15.6
Invasive 79 72.5
Histological tumor gradeb
G1 14 12.8
G2 9 8.3
G3 80 73.4
unknown 6 5.5
Histological tumor gradec
Low grade 15 13.8
High grade 94 86.2
Tumor stagec
pTx 1 0.9
pTis 13 11.9
pTa 16 14.7
pT1 12 11.0
pT2 25 22.9
pT3 31 28.4
pT4 11 10.1
Concomitant CIS
Negative 26 23.9
Positive 52 47.7
Unknown 31 28.4
Lymph node status
Negative 41 37.6
Positive 18 16.5
Unknown 50 45.9
aOnly patients with primary bladder cancer were included; baccording to WHO
1973 classification; caccording to WHO 2004 classification.
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with a product size of 89 bp. The annealing temperature
for both primer sets was 60°C. The relative mRNA-
quantification was analyzed using comparative CT
methods in comparison to GAPDH-expression.Bisulfite-modification and methylation-specific PCR (MSP)
Bisulfite conversion of 1 μg of all genomic DNA was
achieved using the EZ-DNA-Methylation-Kit (Zymo
Research, Orange/CA, USA) and the precipitate was
eluted in 20 μl of Tris-Ethylenediaminetetraacetic acid
(EDTA)-buffer. Thereafter, 1 μl was amplified in a methyla-
tion specific PCR using an optimized PCR buffer. MSP-
Primers, specific for the unmethylated ST6GAL1-promotor
sequence, were used and read as follows: 5′-GAA GAC
GTT TGG GGT ATT GTT CGG C-3′ (M sense) and 5′-
TAC ACT CTC GAC CGC GAA AAC TAC G-3′ (M anti-
sense); 5′-GGG AAG ATG TTT GGG GTA TTG TTT
GGT G-3′ (U sense) and 5′-TCA CTC ACT ACA CTC
TCA ACC GCA AAA ACT ACA-3′ (U antisense). The
reaction consisted of 400 nM of the specific primer pairs
and 1.25 mM of individual dNTPs. The PCR was com-
pleted using the hotstart-PCR method, where 1.25 units of
Taq-DNA-Polymerase (Roche Diagnostics, Mannheim,
Germany) were given to the mixture when the reaction
reached a temperature of 80°C. The PCR conditions were:
95°C for 5 min, followed by 35 cycles of the following
sequence: 95°C for 30 s, 56°C for 30 s, 72°C for 30 s
and 72°C for 5 min. The amplified PCR product was
then run on a 3% low-range ultra-agarose gel (Bio-Rad
Laboratories, Hercules/CA, Germany) with ethidium
bromide and then visualized using ultraviolet light.In vitro demethylation of genomic DNA
Bladder cell lines were seeded in a 6 well dish with a con-
centration of 3 × 104 cells/cm. A demethylating substance,
5-aza-2′-deoxycytidine (DAC) in a concentration of 1 μM
(Sigma-Aldrich, Deisenheim, Germany), was added with
fresh medium on day 1, 2 und 3. In addition, 300 nM of
the histone deacetylase inhibitor trichostatin A (TSA,
Sigma-Aldrich) was added on day 3. The cells were culti-
vated in fresh medium after every treatment and harvested
on the fourth day for RNA extraction.ST6GAL1 immunohistochemistry
2 μm slides of formalin fixed paraffin embedded (FFPE)
bladder tissues were stained with ST6GAL1 monoclonal
antibody LN1 clone with 1:100 dilution (MAB6959,
Abnova, Walnut, CA, USA). Heat induced antigen re-
trieval in pH 9.0 EDTA buffer was performed and
samples were blocked with peroxide blocking solution
from DAKO (DAKO, Hamburg, Germany). DAKO
K5007 kit was used as a detection method, according to
the manufacturer’s instructions. For visualization 3,3′-
diaminobenzidine (DAB) and haematoxylin counter-
stain was used. Staining was evaluated according to an
adapted semi quantitative scoring system by Remmele
and Stegner [23].
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hypermethylation in an independent set of bladder tumors
In order to independently assess ST6GAL1 mRNA expres-
sion and DNA methylation we used public data from both
primary invasive [24] and papillary bladder cancer tissues
from “The Cancer Genome Atlas” (TCGA) data portal
(https://tcga-data.nci.nih.gov). These comprise data of
overall n = 184 patients from two independent platforms:
Illumina Infinium DNA methylation chip (HumanMethy-
lation 450) and Illumina HiSeq gene expression. The data
can be explored through the cBio Cancer Genomics Portal
(http://cbioportal.org). For cohort characteristics of ana-
lyzed TCGA samples in this current study see Additional
file 1: Table S1.
Statistical data analysis
All statistical analysis was done using SPSS 17.0 (SPSS
Software GmbH, Munich). Results were considered to
be statistically significant given a p value of <0.05. All
statistical tests were performed 2 sided. In order to
compare two groups, the non-parametric Mann–Whitney
U-test was implemented. In case of more than two gener-
ated groups the Kruskal-Wallis test and Dunn’s multiple
comparison test was used. Any correlation to clinical
pathological factors and molecular parameters were ana-
lyzed using a descriptive Fisher’s exact-test. Correlation
between ST6GAL1 expression (TCGA Illumina HiSeq plat-
form) and ST6GAL1 methylation data (TCGA HM450
platform) was performed by calculating a Spearman correl-
ation coefficient.
Results
ST6GAL1 mRNA is differently expressed in human bladder
cancer
Previously, Wild and colleagues described novel candidate
genes differentially expressed in human bladder cancer
[22]. Based on that, we re-analyzed the DNA microarray
data set by using in silico database mining procedures
identifying novel candidates with differential expression in
the course of bladder cancer progression (data not
shown). As such we frequently detected ST6GAL1 expres-
sion loss by 2.6-fold in pTa and by 3.4-fold in pT1/pT2
bladder tumors. Therefore we aimed to study for the first
time ST6GAL1 expression and regulation in bladder
cancer.
Semi-quantitative ST6GAL1 real-time PCR expression
analysis was performed on 51 bladder cancer tissue
samples including flat (n = 12 CIS), papillary non-invasive
(n = 13 pTa), and muscle-invasive (n=26 pT2-4) bladder
tumor samples (Figure 1A). Detailed cohort statistics can
be found in Table 1. Overall, no significant trend was
observed when normal urothelium was compared with a
mixed tumor cohort (1B). Classification of these samples
by tumor subtypes, however showed that ST6GAL1mRNA expression tends to be downregulated (fold
change, FC: 0.36) in muscle-invasive tumors when com-
pared to normal urothelium (NU) (n = 15). In contrast,
ST6GAL1 mRNA expression in papillary non-invasive
tumors was found to be increased (FC: 1.88) (Figure 1C).
A tight association between loss of ST6GAL1 mRNA
expression and advanced bladder tumor stages (pT2-pT4;
invasive subtype) was significantly underscored by using
Fisher’s exact test (Table 2).
Facing this heterogeneous expression in bladder tumors,
we performed further real-time PCR expression analysis
using eight patient-matched specimens including NU,
CIS, and invasive tumor tissues from each single patient
allowing a precise assessment of ST6GAL1 mRNA
expression in the course of bladder cancer progression
(Figure 1D). In five of the analyzed patients, a clear down-
regulation (<0.5 FC) of ST6GAL1 mRNA expression was
detected in solid tumors, i.e. in invasive stages. Only one
patient showed an increase with a FC >2 in ST6GAL1
gene expression and two patients an insignificant change
(Figure 1D), not impairing a pronounced loss of ST6GAL1
in invasive tumor stages.
ST6GAL1 protein expression in human bladder cancer
In light of differential ST6GAL1 mRNA expression in
bladder cancer, we performed immunohistochemical
ST6GAL1 protein expression in NU as well as in bladder
tumor tissues. ST6GAL1 protein staining was quantified
according to an adapted immunoreactive score (IRS) de-
veloped by Remmele and Stegner [23]. In NU ST6GAL1
was detected cytoplasmatically in all urothelial cell layers,
with strongest abundance in superficial (“umbrella”) cells
(Figure 2A). In contrast, invasive bladder tumors were
characterized by a decreased ST6GAL1 protein staining
(Figures 2B-D): 69.2% (n = 45/65) of all analyzed tumors
showed an ST6GAL1 protein staining of IRS ≤ 4 and
25.6% (16/65) exhibited an almost complete loss (IRS = 0)
of ST6GAL1 protein (Figure 2G). A correlation analysis
with clinico-pathological characteristics revealed a signifi-
cant association (p = 0.017) of ST6GAL1 protein reduc-
tion and the existence of lymph node metastasis (Table 3).
ST6GAL1 promoter hypermethylation is associated with
ST6GAL1 expression loss in human bladder cell lines
Given the observation of ST6GAL1 expression loss in the
course of bladder cancer progression, we attempted to
decipher the molecular cause for ST6GAL1 gene silencing.
Recently, DNA methylation in promoter regions, a fre-
quent and well-known epigenetic mechanism of gene
inactivation during carcinogenesis was shown in breast
cancer [25]. Therefore, we assessed whether this epigenetic
modification might be responsible for ST6GAL1 downreg-
ulation in bladder cancer as well. Analysis of the ST6GAL1
gene promoter using the genomic DNA information
Figure 1 ST6GAL1 mRNA expression analyses in human bladder cancer. (A) Real-time PCR based ST6GAL1 mRNA expression analyses of 51
tumor samples (UC) compared to normal urothelium (NU) samples (n = 15). The median expression level of NU was set to 1. Vertical lines: ± standard
error of margin (s.e.m.). (B) Box plot showing median ST6GAL1 mRNA expression in normal urothelium compared to all analyzed urothelial cancer
samples. Horizontal lines: grouped medians. Boxes: 25–75% quartiles. Vertical lines: range, peak and minimum, ns: not significant. (C) Itemized box plot
demonstrating median ST6GAL1 mRNA expression in normal urothelium (NU), non-invasive papillary tumors (PAP), CIS, and invasive bladder tumors
(INV). Horizontal lines: grouped medians. Boxes: 25–75% quartiles. Vertical lines: range, peak and minimum. (D) Real-time PCR based ST6GAL1 mRNA
expression analyses of patient triplets with matched normal urothelium, CIS and invasive tumor samples. Matched CIS and solid tumors were
normalized to the corresponding NU, respectively. Vertical lines: + s.e.m.
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Table 2 Clinico-pathological parameters in relation to
ST6GAL1 mRNA expression
ST6GAL1 mRNA levelb
na low high P-valuec Spearman rs
Parameter:
Age at diagnosis
≤69 years 24 10 14 0.977 −0.004
>69 years 19 8 11
Gender
Female 9 5 4 0.273 0.169
Male 41 14 27
Tumor subtype
Non-invasive 13 2 11 0.017 −0.402
Invasive 26 15 11
Histological tumor graded
Low grade 11 1 10 0.035 −0.316
High grade 39 18 21
Tumor staged
pTa-pT1 16 4 12 0.099 −0.313
pT2-pT4 23 13 10
aOnly patients with primary bladder cancer were included; bcut-off: 0.5 in
relation to NU expression; cFisher’s exact test; daccording to WHO 2004
classification, significant p-values are marked in bold face.
Figure 2 ST6GAL1 protein expression in human bladder cancer.
(A) + (B) matched samples of patient #1 with (A) normal urothelium
with accentuated ST6GAL1 protein expression in superficial
(“umbrella”) cells and (B) complete loss of ST6GAL1 protein in the
poorly differentiated invasive bladder cancer. (C) + (D) Matched
samples of patient #2 with (C) normal urothelium with accentuated
ST6GAL1 protein expression in superficial (“umbrella”) cells and
(D) moderate ST6GAL1 protein expression in the invasive bladder
cancer (staining intensity 2). (E) Positive control: prostate sample
with strong ST6GAL1 staining (staining intensity 3). (F) Negative
control: prostate sample with no staining (staining intensity 0).
(G) Histogram of ST6GAL1 protein expression (immunoreactive
score, IRS) distribution among all tumor samples.
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mer program [26] identified two CpG-rich islands between
genomic positions 186,930,485 and 187,078,553 on
chromosome 3 which met the following criteria: DNA
region: ≥200bp; Obs/Exp: ≥0.6; %GC: ≥50. The ST6GAL1
promoter region analyzed by methylation specific PCR
(MSP) is located in the non-coding exon 1 next to the tran-
scription start site (TSS) and encodes potential regulatory
sequences such as the ubiquitous transcription factor II B
(TFIIB) recognition element (BRE: ccgCGCC ) (Figure 3A).
MSP analysis showed indeed distinct DNA methylation
in the human bladder cancer cell line J82 and RT112 at the
ST6GAL1 promoter region. Of importance the ST6GAL1
promoter region of the immortalized bladder cell line
UROtsa originally derived from normal urothelium
remained unmethylated. Reflecting the variance seen in
our tumor population, the RT4 papillary-invasive cell line
showed no ST6GAL1 promoter methylation (Figure 3B).
This unmethylated configuration of the ST6GAL1 pro-
moter correlated with a strong ST6GAL1 expression in
both cell lines UROtsa and RT4, whereas a weak ex-
pression in J82 and a nearly complete loss of ST6GAL1
mRNA expression in RT112 cancer cells was observed
(Figure 3C).
In vitro demethylation assays of human bladder cell
lines (RT112, RT4, J82 and UROtsa) were performed to
further underscore the functional association between
ST6GAL1 promoter methylation and gene transcription.
Table 3 Clinico-pathological parameters of high grade,
invasive bladder tumors in relation to ST6GAL1 protein
expression
ST6GAL1 IRSb
na low(IRS 0–3) high(IRS 4–12) P-valuec Spearman rs
Parameter:
Age at
diagnosis
≤69 years 27 10 17 0.987 0.002
>69 years 38 14 24
Gender
Female 21 8 13 0.894 0.017
Male 44 16 28
Histological
tumor graded
G2 7 4 3 0.247 0.146
G3 58 20 38
Tumor stagee
pT1-pT2 29 7 22 0.056 −0.238
pT3-pT4 36 22 19
Lymph node
status
Negative 39 11 28 0.017 −0.321
Positive 16 10 6
aOnly patients with primary bladder cancer were included; bcut-off: median
immunoreactive score (IRS) according to Remmele and Stegner [23]; cFisher’s
exact test; daccording to WHO 1973 classification according to WHO 2004
classification; eaccording to WHO 2004 classification; significant p-values are
marked in bold face.
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ST6GAL1 mRNA expression approximately by 18,000
fold in highly methylated RT112 tumor cells (Figure 3D).
ST6GAL1 mRNA expression in J82 cells was solely
marginal re-expressed after DAC and TSA treatment.
ST6GAL1 mRNA in both normal-like UROtsa and RT4
bladder tumor cells harboring an unmethylated ST6GAL1
promoter served as control and were not further inducible
by DAC/TSA (Figure 3D). These data indicate that epigen-
etic configurations at the ST6GAL1 promoter region are
involved in the regulation of ST6GAL1 expression.
ST6GAL1 promoter methylation is tightly associated with
ST6GAL1 expression loss in primary bladder tumors
Based on the promoter methylation in bladder cancer cell
lines, the ST6GAL1 promoter methylation in primary
human bladder cancer samples including CIS (n = 82) was
analyzed using MSP technology. NU tissues (n = 23)
served as control. All analyzed NU tissues showed
unmethylated ST6GAL1 promoters; representative MSP
results demonstrating an aberrant ST6GAL1 promoter
region methylation status in bladder tumors are shown in
Figure 4A. Overall, ST6GAL1 promoter methylation wasdetected in 32.9% (27/82) of bladder cancer samples.
Upon closer examination with respect to the individual
growth forms, the methylation frequency in invasive
tumors was 53.6% (22/41), whereas only one out of 12
(8.3%) of the CIS samples showed aberrant ST6GAL1
promoter methylation. The non-invasive pTa phenotype
displayed a methylation frequency of 13.8% (4/29). Such
disparity between the two growth forms is not surprising,
as findings by Wolff et al. suggested a general pattern of
hypomethylation in noninvasive urothelial tumors [27].
Subsequently we correlated these methylation results
with the ST6GAL1 mRNA expression in order to deter-
mine whether the promoter methylation was responsible
for the loss of gene expression in muscle-invasive tumors.
Unmethylated NU tissues served as a control (expression
level set to 1). Compared to these, unmethylated UC
tumors showed a median expression rate of 1.512. In
contrast methylated bladder tumors showed a significant
(p < 0.05) reduction in ST6GAL1 mRNA expression down
to 0.338 (Figure 4B). The significance of the correlation be-
tween loss of ST6GAL1 gene expression and its promoter
methylation was statistically confirmed by using a Fisher’s
exact test (p = 0.022) (Table 4).
In order to strengthen our findings, we analyzed
ST6GAL1 promoter methylation and gene expression in a
dataset of independent studies (The Cancer Genome Atlas
(TCGA) (https://tcga-data.nci.nih.gov)), in total represent-
ing 184 different bladder cancer samples (for cohort
characteristics see Additional file 1: Table S1). Based on
the TCGA data we verified downregulation of ST6GAL1
gene expression in bladder cancer in comparison to
normal bladder tissues (Figure 5A). Furthermore,
ST6GAL1 promoter hypermethylation of six CpG sites
(located from −98 bp to +584 bp with respect to the TSS, i.
e. covering the MSP analyzed region) was confirmed in
bladder cancer samples underscoring a homogenous
methylation pattern within the ST6GAL1 promoter locus
(Figure 5B) compared to normal solid tissues. Importantly, a
highly significant (p < 0.001) inverse correlation (Spearman
coefficient: −0.733) of aberrant ST6GAL1 promoter methy-
lation and ST6GAL1 mRNA expression was verified in this
dataset (Figure 5C).Discussion
Accumulating evidence shows that ST6GAL1 is aberrantly
expressed in various cancer entities such as colon, breast,
and epithelial tumor types [14,17], and most studies
propose an oncogenic role for ST6GAL1 [16-20,28]. How-
ever, its role in tumorigenesis remains controversial [21].
Up to date, knowledge about a possible role of ST6GAL1
in human bladder cancer is still lacking. In the present
study we aimed to describe for the first time ST6GAL1 ex-
pression and regulation in human bladder carcinogenesis.
Figure 3 ST6GAL1 promoter methylation in human bladder cell lines correlates with ST6GAL1 mRNA expression. (A) Schematic map of
the human ST6GAL1 promoter region including the relative positions of analyzed CpG dinucleotides using MSP (MSP primer binding sites are
indicated by arrows) that is located within the non-coding exon 1 region. Two predicted CpG islands are located between base −442 and base +136
as well as between base +145 and base +878 in relation to the transcription start site (TSS). +1: ST6GAL1 TSS. Orange and yellow boxes illustrating gene
transcription-relevant regulatory elements statistically identified by using the Genomatix data base (http://www.genomatix.de/): BRE: Transcription
factor II B (TFIIB) recognition element (score: 1.0, position in relation to TSS: 282–288 bp); SP4: Ubiquitous GC-Box factors SP1/GC recognition element
for SP4 TF (score: 0.89, position in relation to TSS: 287–303 bp). (B) Representative MSP analysis illustrating the ST6GAL1 promoter methylation status of
human bladder cell lines RT112, RT4, J82 and UROtsa. Band labels with U and M represent an unmethylated and methylated DNA locus. Bisulphite-
converted unmethylated, genomic (U-co) and polymethylated, genomic (M-co) DNA were used as positive controls. NTC: non-template control.
(C) Comparison of ST6GAL1 mRNA expression of human bladder cell lines showing an unmethylated ST6GAL1 promoter hypermethylation (UROtsa
and RT4) with ST6GAL1 methylated J82 and RT112 cells. Vertical lines: + s.e.m. (D) DNA demethylation of the ST6GAL1 promoter correlates with ST6GAL1
re-expression in vitro. Real-time PCR of ST6GAL1 mRNA expression demonstrated a clear ST6GAL1 re-expression after treatment with both DAC (+) and
TSA (+) only in the RT112 bladder cell line. Non-treated cells were set to 1. Error bars: + s.e.m.
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expression in bladder tumors compared to normal urothe-
lium. Using real-time PCR, we were able to consistently
show ST6GAL1 mRNA expression in normal urothelial
tissue. Initial analysis of a mixed-stage tumor cohort failed
to reveal a clear pattern of up- or downregulation in
ST6GAL1 expression. However, when these samples were
classified according to subtypes/stages, two distinct pat-
terns emerged. Well-differentiated non-invasive papillary
tumors were predominately characterized by an increase
in ST6GAL1 expression, while invasive tumors (pT2-4)
displayed a significant decrease in ST6GAL1 expression.
Such disparity is, however, hardly surprising as bothtumor forms are characterized by a unique molecular
profile, which extends to the epigenetic level [8,10,29]. In
addition, Seales et al. showed that expression of oncogenic
RAS in HD3 colonocytes caused an increase in α-2,6-sia-
lylation of β1-integrins by ST6GAL1, and the expression
of dominant-negative RAS results in decreased sialylation
[30]. Therefore, an upregulation of ST6GAL1 in papillary
tumors, which often carry a mutated RAS gene [7] can be
viewed in this context. Thereafter, using patient matched
samples, a sequential loss of ST6GAL1 could be demon-
strated throughout the course of bladder cancer develop-
ment beginning in the CIS stage and continuing to invasive
disease when compared with the corresponding normal
Figure 4 ST6GAL1 promoter hypermethylation in primary human bladder cancer is associated with loss of ST6GAL1 mRNA expression.
(A) Representative MSP results of the ST6GAL1 promoter methylation status in four papillary non-invasive pTa low grade tumors (PAP) as well as
four invasive high grade bladder cancer (INV) samples in comparison to four normal tissue specimens (NU). Bands labeled with U and M show
unmethylated and methylated DNA, respectively. Percent values reflect methylation frequency (M frequency). Bisulphite-converted unmethylated,
genomic (U-co) and polymethylated, genomic (M-co) DNA were used as positive controls. DNA control: genomic, non- bisulphite-converted DNA,
NTC: non-template control. (B) Box plot illustrating ST6GAL1 mRNA downregulation according to hypermethylated ST6GAL1 promoter status in
bladder cancer (UC). (U): unmethylated tumors. (M): Methylated tumors. Horizontal lines: grouped medians. Boxes: 25–75% quartiles. Vertical lines:
range, peak and minimum; *p < 0.05.
Table 4 Clinico-pathological parameters in relation to
ST6GAL1 promoter methylation
ST6GAL1 methylationb
na negative positive P-valuec Spearman rs
Parameter:
Age at diagnosis
≤69 years 29 19 10 0.858 −0.24
>69 years 31 21 10
Gender
Female 9 6 3 1.000 <0.001
Male 51 34 17
Tumor subtype
Non-invasive 16 12 4 0.343 0.167
Invasive 31 18 13
Histological tumor
graded
Low grade 14 11 3 0.347 0.139
High grade 46 29 17
Tumor staged
pTa-pT1 19 15 4 0.073 0.276
pT2-pT4 27 14 13
ST6GAL1 mRNA
expressione
Low 18 9 9 0.022 −0.355
High 30 25 5
aOnly patients with primary bladder cancer were included; bbased on MSP;
cFisher’s exact test; daccording to WHO 2004 classification; ecut-off: 0.5 in
relation to NU expression; significant p-values are marked in bold face.
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http://www.biomedcentral.com/1471-2407/14/901urothelium. Consistent with these findings, we observed
weak ST6GAL1 protein expression in invasive bladder
tumors. Indeed, more than one fourth of high-grade cancer
tissues showed complete loss of ST6GAL1 protein. These
observations seem to contradict those by Swindall and col-
leagues, who reported a general upregulation of ST6GAL1
in epithelial tumors; however, their data was based on a
very small sample population of ovarian, stomach and
prostate cancers. Most notably, bladder cancer was not
included in this cohort [28]. Of clinical importance, in our
comprehensive sample collection, ST6GAL1 expression
loss correlated with clinico-pathological metastasis, i.e.
regional lymph node invasion, implying a possible tumor
suppressive role for ST6GAL1 in advanced bladder cancer
stages.
It is well known that epigenetic alterations, such as
DNA methylation, are common mechanisms contributing
to tumorigenesis and tumor progression [29,31,32]. Ana-
lysis of aberrant DNA methylation has rapidly garnered
interest in cancer risk assessment, diagnosis, as well as
prognosis and therapy monitoring [33,34]. The progressive
increase in de novo methylation of CpG islands in urothe-
lial carcinoma suggests that epigenetic gene silencing is
involved in the development of UC [10]. Interestingly,
Fleischer et al. has previously shown that the ST6GAL1
promoter sequence contains distinct CpG islands whose
DNA methylation caused loss of ST6GAL1 expression in
breast cancer [25]. As such, we sought to determine
whether promoter methylation could be responsible for
ST6GAL1 gene inactivation in bladder cancer as well.
Indeed, we identified a tumor-specific ST6GAL1 promoter
hypermethylation, which appeared to be more frequently
associated with poorly differentiated and advanced tumor
Figure 5 Tumor-specific ST6GAL1 promoter hypermethylation is
associated with ST6GAL1 gene silencing in an independent
TCGA data set. (A) ST6GAL1 expression in bladder tumor samples
from the TCGA data portal. Red: high expression, black: mean
expression and green: low expression. Left panel: sample type
(dark grey: primary tumor; white: solid normal tissues). Right panel:
ST6GAL1 mRNA expression. (B) DNA methylation of the ST6GAL1
promoter analyzed in bladder cancer samples from TCGA data
portal. Red: high methylation, white: mean methylation; blue: low
methylation. Right panel: sample type (dark grey: primary tumor;
white: solid normal tissues). Left panels: values of ST6GAL1 DNA
methylation for each available CG number. The relative positions of
six analyzed CpG duplets within the ST6GAL1 promoter region
covering the MSP analyzed region (+224 to +346) are indicated. +1:
ST6GAL1 TSS. CG25372568 position in relation to the stated TSS: +272.
(C) Inverse correlation of ST6GAL1 mRNA expression and its DNA
methylation status in primary bladder cancer samples. ρ: Spearman
correlation coefficient.
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http://www.biomedcentral.com/1471-2407/14/901stages. Importantly, a highly significant inverse correlation
between ST6GAL1 expression and ST6GAL1 promoter
hypermethylation was observed in these bladder tumors.
It appears that loss of ST6GAL1 expression in bladder
cancer is not only a common event, but also tightly associ-
ated with epigenetic changes within the ST6GAL1 pro-
moter region. This hypothesis was strengthened using an
independent bladder tumor data set based on The Cancer
Genome Atlas (TCGA) portal. Finally, demethylating treat-
ment of methylated ST6GAL1 bladder cancer cell lines
with 5-aza-2-deoxycytidine clearly restored ST6GAL1 ex-
pression, thus functionally confirming a strong correlation
between ST6GAL1 expression and its promoter hyperme-
thylation. Our findings give the first indications that this
major epigenetic mechanism could be important in the
regulation of ST6GAL1 expression in bladder cancer as
well. Bearing in mind that this is a known mechanism to
mediate the silencing of tumor suppressor genes, a possible
tumor suppressive role of ST6GAL1 in the course of blad-
der cancer progression could be hypothesized even though
further studies are needed to analyze, in depth, ST6GAL1
function in human bladder cancer subtypes.
Conclusions
Our study characterizes for the first time ST6GAL1
expression and regulation during bladder cancer develop-
ment. ST6GAL1 loss is caused by aberrant ST6GAL1
promoter methylation potentially indicating a tumor
suppressive role in bladder carcinogenesis. Further investi-
gation is warranted in order to more precisely assess the
mechanism by which ST6GAL1 contributes to bladder
cancer formation, progression and invasion.
Additional file
Additional file 1: Table S1. Clinico-pathological parameters of 184
bladder cancer specimens (TCGA) analyzed in this study.
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